0.48 USD
▼-0.03-5.45%
盘后 0.47 0.00%
2026-11-20
市值
$1.76M
市盈率
—
EPS
-17.31
股息率
—
52 周区间
0.46 – 24.80
成交量
47.78K
Beta
1.37
目标价
—
52W 低 0.4652W 高 24.80
价格走势
公司简介
Calidi Biotherapeutics, Inc., a biotechnology company, develops targeted therapies to deliver genetic medicines to distal sites of disease. The company offers CLD-101, which is in Phase 1b/2 clinical trial for the treatment of newly diagnosed high grade glioma, as well as in Phase 1 dose-escalation clinical trial for recurrent high-grade glioma; CLD-201 product for solid tumors, such as breast cancer, head and neck cancer, and sarcoma; and CLD-401 for the treatment of metastatic solid tumors. It also offers oncolytic virus platforms, such as Ne...